| |
01/05/2009
FDA Announces Class I Recall Of Ophthalmic Surgical Device
The U.S. Food and Drug Administration announced a Class I recall of lot no. UD30654 of Healon D, an ophthalmic viscosurgical device (OVD) manufactured by Advanced Medical Optics Inc. (AMO) of Santa Ana, Calif. OVDs are viscoelastic materials used to maintain space in the eye during surgery. Typically, OVDs are pre-packaged in a syringe and are applied using a small tube. On Oct. 30, 2008, AMO voluntarily recalled all 4,439 units of Healon D lot no.
more info
|
01/04/2009
Bright Lights, Not So Big Pupils
A team of Johns Hopkins neuroscientists has worked out how some newly discovered light sensors in the eye detect light and communicate with the brain. The report appears online this week in Nature. These light sensors are a small number of nerve cells in the retina that contain melanopsin molecules.
more info
|
01/02/2009
The Discovery Eye Foundation Recommends Eye Care As A New Year's Resolution
New Year's Day is a time of year when many individuals take a look forward to the coming year. New Year's resolutions, such as weight loss, and exercise are common, but medical experts at The Discovery Eye Foundation (DEF) are recommending you include making eye care a priority. Eye care is not usually something that tops everyone's New Year resolution lists.
more info
|
01/02/2009
Purchasing Contact Lenses Online
When purchasing lenses you obviously want to get the best deal possible and it has shown over and over again that the Internet is where the best prices are. However, with that said we also have to mention that purchasing contact lenses online comes with some downsides. To clarify all the important points that this topic sustains we created this guide with the pros, cons, online safety and other important dos and don'ts.
more info
|
01/01/2009
Resolvyx Announces Initiation Of Phase I/II Clinical Trial Of Novel Resolvin Therapeutic RX-10045 In Patients With Dry Eye
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating a resolvin therapeutic, RX-10045, in a Phase I/II clinical trial in patients with moderate-severe dry eye syndrome. RX-10045 is a synthetic analog of RvE1, a naturally occurring resolvin with potent anti-inflammatory and cell-sparing activities in laboratory testing.
more info
|
|
|
|
